Literature DB >> 25360840

Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial.

Li-Ying Wang, Jian-Yuan Tang, Jun Liu, Wei Lu, Ya-Nan Yu, Bi-Wei Chen, Hong-Li Wu, Li-Ya Su, Zhi-Wei Jing, Si-Yuan Hu, Xiang-Ling Liu, Xi-Yan Yang, Guo-Xin Li, Bo Dong, Dong-Hai Wang, Jie Xue, Xiao-Feng Wang, Zhuo-Ming Li, Shu-Rong Liu, Song-Shan Liu, Qi-Guang Chen, Lei Zhang, Zhong Wang1, Chun-Ti Shen, Yong-Yan Wang.   

Abstract

OBJECTIVE: To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment.
METHODS: Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS) tablets for 8 weeks. Global similarity degree analysis and nonlinear mixed effects modeling (NONMEM) were employed to reveal the cutoff points and influencing factors in dynamic changes in the SAP phenotypic group. The phenotypic group was defined as the six phenotypes in SAP, including angina, choking sensation in the chest, palpitations, dark purple lips, ecchymosis on the tongue, and fine-choppy pulse, which were quantitatively evaluated on Days 0, 14, 28, 42, and 56.
RESULTS: Variation in the six individual phenotypes and distribution of the SAP phenotypic profile were similar between the two experimental groups, but cutoff points for changes in the SAP phenotypic group were 7.28 and 10.73 weeks in XXK and CDS groups, respectively. Degree of severity of SAP as well as study site significantly affected the tendency for change in the SAP Xueyu Zheng in both XXK and CDS treatment groups. Different Chinese patent drugs affected the tendency for change in phenotypic group in patients with SAP. XXK was superior to CDS in controlling a clinical phenotypic group.
CONCLUSION: Based on global similarity degree analysis and NONMEM, the cutoff point and influencing factors in phenomic variation of SAP may be determined, to improve the development and modification of treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25360840     DOI: 10.2174/1570161112666141014151858

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  4 in total

1.  Editorial: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics.

Authors:  Zhong Wang; Dayue Darrel Duan; Yong-Yan Wang
Journal:  Curr Vasc Pharmacol       Date:  2015       Impact factor: 2.719

2.  Adjuvant treatment of coronary heart disease angina pectoris with Chinese patent medicine: A prospective clinical cohort study.

Authors:  Yijia Liu; Zhu Li; Dandan Shen; Yanqi Song; Mengnan Huang; Xiaoxue Xue; Jing Xie; Ziyi Jiao; Shuming Gao; Yilan Xu; Shan Gao; Xianliang Wang; Qiang Xu; Sheng Gao; Chunjie Li; Lin Li; Kaijun Niu; Chunquan Yu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.889

Review 3.  Diosgenin and Its Analogs: Potential Protective Agents Against Atherosclerosis.

Authors:  Dan Wang; Xiaolong Wang
Journal:  Drug Des Devel Ther       Date:  2022-07-17       Impact factor: 4.319

4.  The Clinical Efficacy of Phytochemical Medicines Containing Tanshinol and Ligustrazine in the Treatment of Stable Angina: A Systematic Review and Meta-Analysis.

Authors:  Li Gao; Tong Wu; Juan Wang; Zhuoran Xiao; Chunhua Jia; Wei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-02       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.